[go: up one dir, main page]

WO2013115456A1 - Aliment, substance cosmétique, ou composition pharmaceutique contenant un extrait supercritique de gingembre et un extrait de résidu de persil japonais fermenté - Google Patents

Aliment, substance cosmétique, ou composition pharmaceutique contenant un extrait supercritique de gingembre et un extrait de résidu de persil japonais fermenté Download PDF

Info

Publication number
WO2013115456A1
WO2013115456A1 PCT/KR2012/008252 KR2012008252W WO2013115456A1 WO 2013115456 A1 WO2013115456 A1 WO 2013115456A1 KR 2012008252 W KR2012008252 W KR 2012008252W WO 2013115456 A1 WO2013115456 A1 WO 2013115456A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
extract
fermented
ginger
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/008252
Other languages
English (en)
Korean (ko)
Inventor
양선아
이은주
정연섭
최희돈
김민주
임효권
이삼빈
이인선
김형대
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE(KHIDI)
Industry Academic Cooperation Foundation of Keimyung University
Korea Health Industry Development Institute
Original Assignee
KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE(KHIDI)
Industry Academic Cooperation Foundation of Keimyung University
Korea Health Industry Development Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE(KHIDI), Industry Academic Cooperation Foundation of Keimyung University, Korea Health Industry Development Institute filed Critical KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE(KHIDI)
Publication of WO2013115456A1 publication Critical patent/WO2013115456A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A61K8/022—Powders; Compacted Powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A61K8/0229—Sticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
    • A61Q1/06—Lipsticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction

Definitions

  • the present invention relates to a food composition, a cosmetic composition, and a pharmaceutical composition containing a ginger supercritical extract and a fermented parsley extract as an active ingredient.
  • Inflammatory skin diseases are diseases in which a series of clinical signs and symptoms, such as itching, swelling, erythema, peeling, etc., are caused by various stimulating factors causing a series of inflammatory reactions in the skin epithelium.
  • Inflammatory skin diseases include atopic dermatitis, contact dermatitis, seborrhoic dermatitis and acne.
  • Atopic dermatitis is generally used in the same sense as eczema, which is an eczema-like skin lesion that occurs in people with atopic dermatitis.
  • the cause of atopic dermatitis has not been identified to date and is known to have a genetic tendency, and now it is persuaded that it is a kind of autoimmune disease. Unlike normal eczema or dermatitis, it shows unusual symptoms and course, and 70 to 80% of pediatric eczema is present, and it occurs in adults recently.
  • Contact dermatitis is an inflammation of the skin caused by contact with an external substance. It has the same symptoms as acute eczema, but differs from eczema in that it occurs as a response to certain externally acting substances.
  • Seborrheic dermatitis is a dermatitis that occurs well in areas with high secretion of sebum, such as the head, forehead, and armpits. It is also called seborrheic eczema. A lot of erythema and slender slits (dandruff) occur and appear in many 20s and 40s. Unlike ordinary eczema, the disease is caused by constitution or sebaceous abnormalities, sensitive to sunlight or heat, often worsening in spring and autumn, and easy to recur.
  • Acne is a chronic inflammatory disease of hair follicles and sebaceous glands, the main cause of the increase in sebum secretion, anaerobic skin flora propionibacterium acnes (Propionibacterium acnes) is the main cause.
  • Sebum in the acne-prone areas is converted to testosterone (textosterone), a type of male hormone, into dihydrotestosterone, an active form, by 5 alpha-reductase. Is produced by oversecretion.
  • the excess sebum produced above stagnates in the hair follicles and is converted into free fatty acids and various low molecular substances by lipolytic enzymes and chemotactic factors secreted by propionibacterium acne, an anaerobic bacterium that sebum occludes the hair follicles. do. This causes white blood cells to gather around the hair follicles, destroying the hair follicle wall, causing the contents of the hair follicles to leak into the dermis, causing an inflammatory reaction.
  • Acne has been used to treat acne by using an antibiotic such as erythromycin or a method of controlling sebum using estrogen, a female hormone, but there are problems associated with side effects.
  • Vitamin A derivatives, benzoyl peroxide, salicylic acid, triclosan and the like have been used in the cosmetics for the treatment of acne, but these substances have some antibacterial effects, but have problems such as skin redness, skin sensitization, or photosensitivity.
  • the inventors of the present invention are developing a composition having no side effects that can effectively prevent or treat inflammatory skin diseases.
  • Ginger supercritical extract and fermented parsley extract are remarkably excellent in preventing or treating inflammatory skin diseases compared to a single substance.
  • the present invention was completed by confirming that it can be safely used in a living body without showing toxicity.
  • the present invention is to provide a food composition, cosmetic composition or pharmaceutical composition for the prevention or improvement of inflammatory skin diseases such as atopic dermatitis, acne, contact dermatitis by containing ginger supercritical extract and fermented parsley extract as an active ingredient.
  • the present invention provides a composition for the prevention, improvement or treatment of inflammatory skin diseases containing ginger supercritical extract and fermented parsley extract as an active ingredient.
  • the present invention provides a food, cosmetic or pharmaceutical composition containing a ginger supercritical extract and fermented parsley extract as an active ingredient.
  • the content of the active ingredient may be in the range of 0.05% to 95% by weight.
  • the fermented buttercup extract may be contained in 50 to 2000 parts by weight relative to 100 parts by weight of ginger supercritical extract.
  • the ginger supercritical extract is a ginger powder for 1 to 3 hours at a temperature of 35 ⁇ 55 °C, 1 ⁇ 3mL / min at a pressure of 100 ⁇ 400 bar using supercritical carbon dioxide Extracted by supercritical extraction.
  • the fermented buttercup gourd extract is mixed with 40 to 90% by weight of parsley and 10 to 60% by weight of sugar, and fermented at 15 to 30 °C for 8 to 24 months, after filtering the fermentation broth remaining parsley It can be obtained by extracting the hot water.
  • the ginger powder may have an average particle size of 50 ⁇ 500 ⁇ m.
  • the sugar may be one selected from the group consisting of brown sugar, white sugar, syrup and honey.
  • the formulation of the cosmetic composition is a basic cosmetic formulation consisting of a lotion, gel, water-soluble liquid, cream, essence, oil-in-water (O / W) type and water-in-oil (W / O) type;
  • Color cosmetic formulations consisting of oil-in-water or water-in-oil makeup bases, foundations, skin covers, lipsticks, lip gloss, face powders, two-way cakes, eye shadows, cheek colors and eyebrow pencils; It may be any one selected from.
  • Cosmetic composition according to the embodiment may be for skin irritation relief.
  • Cosmetic composition according to the embodiment may be for atopic skin improvement.
  • Cosmetic composition according to the embodiment may be for acne prevention.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory skin diseases, comprising ginger supercritical extract and fermented parsley extract as an active ingredient.
  • Formulation of the pharmaceutical composition for the prevention or treatment of inflammatory skin disease according to the embodiment, PLASTERS, lotion (LPTIONS), linings (LINIMENTS), liquid (LIQUIDS AND SOLUTIONS), aerosol (AEROSOLS) , EXTRACTS, OINTMENTS, FLUIDEXTRACTS, Emulsions, Emulsions, SUSPENSIONS, CAPSULES, CREAMS, Soft or Hard Gelatin Campels, Patches, It may be any one selected from sustained release agent.
  • the present invention can provide a food composition, cosmetic composition or pharmaceutical composition excellent in the prevention and improvement effect on inflammatory skin diseases by containing the supercritical extract of ginger and fermented parsley extract in order to maximize the anti-inflammatory effect of ginger. .
  • Figure 1 is a graph showing the ⁇ -hexosaminidase release inhibitory ability of the ginger supercritical extract according to an embodiment of the present invention.
  • Figure 2 is a graph showing the cytotoxicity of the ginger supercritical extract according to a preferred experimental example of the present invention.
  • Figure 3 is a graph showing the ⁇ -hexosaminidase release inhibition ability of the fermented buttercup gourd extract according to an experimental example of the present invention.
  • Figure 4 is a graph showing the cytotoxicity of the fermented buttercup gourd extract according to an embodiment of the present invention.
  • FIG. 5 is a graph showing ⁇ -hexosaminidase release inhibitory ability (antiallergic) of a composition containing a ginger supercritical extract and a fermented parsley extract according to an embodiment of the present invention.
  • the present invention provides a food composition for the prevention and improvement of inflammatory skin diseases by containing ginger supercritical extract and fermented parsley extract as an active ingredient.
  • the food composition containing the ginger supercritical extract and fermented parsley extract of the present invention has not only a high anti-inflammatory effect but also no toxic effect, which is very suitable for the prevention and improvement of inflammatory skin diseases.
  • the food composition may be used in the form of tea, beverages, dietary supplements, capsules and the like.
  • the present invention also provides a cosmetic composition containing a ginger supercritical extract and fermented parsley extract as an active ingredient.
  • the content of the active ingredient is preferably in the range 0.05 ⁇ 95% by weight relative to the total weight of the composition.
  • the fermented buttercup gourd extract in the composition is preferably contained at 50 to 2000 parts by weight relative to 100 parts by weight of the ginger supercritical extract because the anti-inflammatory effect is high.
  • the ginger supercritical extract is obtained by extracting ginger powder by supercritical extraction for 1 to 3 hours at a flow rate of 1 to 3 mL / min at a temperature of 35 to 55 ° C. and a pressure of 100 to 400 bar using supercritical carbon dioxide.
  • the ginger powder has an average particle size of 50 to 500 ⁇ m, and thus the extraction speed is high.
  • a ginger supercritical extract having a content of 21 to 25% by weight of gingerol, which is one of the anti-inflammatory active ingredients, may be obtained.
  • the fermented buttercup gourd extract is mixed with 40 to 90% by weight of parsley and 10 to 60% by weight of sugar, fermented at 15 to 30 ° C for 8 to 24 months, and then filtered from the fermentation broth to extract the remaining buttercup (residue by-product). It can be obtained by. After hydrothermal extraction of the fermented buttercup gourd may be further subjected to concentration and lyophilization as necessary. According to the above method, the fermented buttercup gourd extract can be obtained with a high yield of 15-25% on average.
  • the sugar may be one or more selected from the group consisting of brown sugar, white sugar, starch syrup and honey.
  • the ginger supercritical extract and the fermented parsley extract each have anti-inflammatory effects, but when the two substances are mixed, they may exhibit increased anti-inflammatory effects.
  • the cosmetic composition containing the ginger supercritical extract and fermented parsley extract of the present invention as an active ingredient may be used for skin irritation relief, atopic skin improvement or acne prevention.
  • Formulation of the cosmetic composition is a cosmetic composition consisting of a lotion, gel, water-soluble liquid, cream, essence, oil-in-water (O / W) type and water-in-oil (W / O) type;
  • Color cosmetic formulations consisting of oil-in-water or water-in-oil makeup bases, foundations, skin covers, lipsticks, lip gloss, face powders, two-way cakes, eye shadows, cheek colors and eyebrow pencils; It may be any one selected from.
  • the present invention provides a pharmaceutical composition for the prevention and treatment of inflammatory skin diseases by containing a ginger supercritical extract and fermented parsley extract as an active ingredient.
  • the pharmaceutical composition containing the ginger supercritical extract and fermented parsley extract of the present invention has not only a high anti-inflammatory effect but also no toxic effect, which is very suitable for the prevention and treatment of inflammatory skin diseases.
  • Formulations of pharmaceutical compositions include PLASTERS, LOTIONS, LINIMENTS, LIQUIDS AND SOLUTIONS, AEROSOLS, EXTRACTS, OINTMENTS, Fluid X FLUIDEXTRACTS, EMULSIONS, SUSPENSIONS, CAPSULES, CREAMS, soft or hard gelatin campels, patches, sustained release agents.
  • the dosage of the supercritical extract of ginger and fermented parsley extract according to the present invention as an active ingredient may be appropriately selected according to the age, sex, condition, and symptoms of an inflammatory skin disease patient, and preferably 1 day 1 To 500 mg of ginger supercritical extract and fermented parsley extract may be smeared on the affected area.
  • a supercritical fluid extraction device (SFT-100XW, Supercritical Fluid Technologies, Inc., Newark, DE, USA) was used, and 18 g of ginger powder having an average particle size of 50 to 500 ⁇ m was extracted into an extraction tank having a volume of 100 mL.
  • the extraction conditions of the samples were carried out with varying pressure at 35, 45, 55 °C temperature to 100, 200, 300, 400 bar, the flow rate of carbon dioxide is 2 mL / min for 2 hours in the dynamic mode to extract the container immediately I received it in (vial).
  • composition of the present invention was prepared by mixing 100 ⁇ g / mL of the prepared ginger supercritical extract and 1000 ⁇ g / mL of the fermented buttercup extract.
  • RAW264.7 cell line (murine macrophage cell line) was obtained from Korea Cell Line Bank (KCLB, Seoul, Korea) and DMEM with 10% FBS (fetal bovine serum) and 1% antibiotics (penicillin / streptomycin) The medium was passaged 2-3 times a week in a 37 °C incubator containing 5% CO 2 .
  • Cytotoxicity against mast cells was measured by MTT method.
  • the cell line RBL-2H3 cells used in this experiment were tested by subcultured through the pre-cultured through the Korea Cell Line Bank (Seoul, Korea).
  • the medium used for cell culture was used after culturing for 2-3 days in 5% CO 2 incubator at 37 ° C using MEM medium containing 10% FBS (fetal bovine serum) and 1% antibiotics (penicillin / streptomycin). .
  • the mast cell line RBL-2H3 was sensitized in 1 ml (2 x 10 5 cells, 24 well plates) for 16 hours with anti-DNP IgE (0.45 ⁇ g / ml) and 30 minutes before activation with DNP-BSA (10 ⁇ g / mL). 20 ml of the sample for each concentration was treated at 37 °C. After the reaction, 25 ⁇ l of the supernatant obtained by centrifugation at 400 ⁇ g for 10 minutes at 4 ° C. was reacted with 25 ⁇ l of substrate p-nitrophenyl-N-acetyl-bD-glucosaminide at 37 ° C. for 1 hour, followed by stop solution (0.1 M NaCO / NaHCO, pH 10) 200 ⁇ l was added to stop and the absorbance was measured at 405 nm to calculate the amount of ⁇ -hexosaminidase.
  • the mixture of ginger supercritical extract and fermented parsley extract is more effective than each single substance, they are mixed in non-toxic concentration intervals to effect the effect on mast cell activation ( ⁇ -hexosaminidase release inhibitory activity).
  • the ginger supercritical extract showed 33% of inhibitory activity at 100 ⁇ g / mL (Fig. 1)
  • the fermented buttercup extract showed 76% of inhibitory activity at 1000 ⁇ g / mL ( Figure 3).
  • the inhibitory activity was 89%, confirming the synergistic effect of the inhibitory effect (FIG. 5).
  • composition containing the ginger supercritical extract and the fermented parsley extract of the present invention can be seen that the skin improvement effect is superior to the case of using only each single substance.
  • cosmetic compositions such as nourishing cream, mist and body wash containing the ginger supercritical extract obtained in Example 1 and the fermented parsley extract were prepared according to a conventional method.
  • a cream containing a mixture of the ginger supercritical extract and fermented buttercup extract according to the present invention prepared in Preparation Example 1 on the affected part of acne patients (7) and atopic dermatitis patients (7) in an appropriate amount 2 After applying for one week in a manner that is applied twice, the state change of the affected part was observed.
  • the present invention can provide a food composition, cosmetic composition or pharmaceutical composition excellent in the prevention and improvement effect on inflammatory skin diseases by containing the supercritical extract of ginger and fermented parsley extract in order to maximize the anti-inflammatory effect of ginger. .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
PCT/KR2012/008252 2012-01-31 2012-10-11 Aliment, substance cosmétique, ou composition pharmaceutique contenant un extrait supercritique de gingembre et un extrait de résidu de persil japonais fermenté Ceased WO2013115456A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2012-0010048 2012-01-31
KR1020120010048A KR101347910B1 (ko) 2012-01-31 2012-01-31 생강 초임계 추출물 및 발효 미나리 박 추출물을 함유하는 식품 조성물, 화장료 조성물 및 약학 조성물

Publications (1)

Publication Number Publication Date
WO2013115456A1 true WO2013115456A1 (fr) 2013-08-08

Family

ID=48905464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/008252 Ceased WO2013115456A1 (fr) 2012-01-31 2012-10-11 Aliment, substance cosmétique, ou composition pharmaceutique contenant un extrait supercritique de gingembre et un extrait de résidu de persil japonais fermenté

Country Status (2)

Country Link
KR (1) KR101347910B1 (fr)
WO (1) WO2013115456A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095918A1 (fr) * 2013-12-24 2015-07-02 Innovative Herbal Products (Aust) Pty Ltd Traitement de la douleur

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019010812A2 (pt) * 2016-12-02 2019-10-01 Symrise Ag misturas cosméticas
KR102738955B1 (ko) * 2022-09-13 2024-12-05 위즈티앤티 주식회사 생강 및 복합 추출물을 함유하는 항진균용 여아용 청결제 조성물
KR102789959B1 (ko) * 2022-09-13 2025-04-04 위즈티앤티 주식회사 생강 및 허브 추출물을 함유하는 항균용 아기 엉덩이 청결제 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002047195A (ja) * 2000-07-12 2002-02-12 Pharmaceutical Industry Technology & Development Center 生姜の有効成分を含む抽出物の製造方法、およびその抽出物を含む医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002047195A (ja) * 2000-07-12 2002-02-12 Pharmaceutical Industry Technology & Development Center 生姜の有効成分を含む抽出物の製造方法、およびその抽出物を含む医薬組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JUSTO, O. R. ET AL.: "Anti Inflammatory Effects of Ginger And Rosemary Extracts Obtainec By Supercritical Fluid Technology", 11TH EUROPEAN MEETING ON SUPERCRITICAL FLUIDS. LS. A.S.F., 2008 *
KWAK, GWI HUI ET AL.: "Zingiber Officinale Protects HaCaT Cells and C57BL/6 Mice from Ultraviolet B-Induced Inflammation", JOURNAL OF MEDICINAL FOOD, vol. 13, no. 3, 2010, pages 673 - 680, XP002717588, DOI: doi:10.1089/jmf.2009.1239 *
KWON, EUN-SOOK ET AL.: "Inhibitory Effects on the Enzymes Involved in the Inflammation by the Ethanol Extracts of Plant Foodstuffs", KOREAN JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, vol. 39, no. 3, 2007, pages 348 - 352, XP053024055 *
LEE, EUN-JU ET AL.: "Comparison of Gingerols in Various Fractions and the Antioxidant Effects of Supercritical Fluid Extracts from Ginger", KOREAN JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, vol. 43, no. 4, 2011, pages 469 - 474, XP053024383 *
PARK ET AL.: "Development of functional drinks from Oenanthe javanica Dc. to enhance hepatic protection", FINAL REPORT, GWACHEON: MINISTRY FOR FOOD, AGRICULTURE, FORESTRY AND FISHERIES, 2008 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095918A1 (fr) * 2013-12-24 2015-07-02 Innovative Herbal Products (Aust) Pty Ltd Traitement de la douleur
US10086033B2 (en) 2013-12-24 2018-10-02 Innovative Herbal Products (Aust) Pty Ltd Treatment of pain

Also Published As

Publication number Publication date
KR20130088665A (ko) 2013-08-08
KR101347910B1 (ko) 2014-01-08

Similar Documents

Publication Publication Date Title
WO2011122869A2 (fr) Composition cosmétique comprenant du coumestrol ou un extrait de fèves contenant du coumestrol, pour les soins de la peau
WO2020060060A1 (fr) Composition cosmétique comprenant un extrait de racine adventive de centella asiatica en tant que principe actif pour le blanchiment de la peau et la réduction des rides
EP2460526A2 (fr) Composition contenant du venin d abeille en tant que substance active pour prévenir et traiter l acné
KR102033089B1 (ko) 항균, 항염증, 피지감소, 각질박리 및 피부진정용 조성물
KR101460569B1 (ko) 진세노사이드 ｆ２를 유효 성분으로 포함하는 주름개선, 피부미백 및 여드름 개선용 화장료 조성물
JP3226700B2 (ja) 美白剤および皮膚外用剤
KR20180043580A (ko) 생약 혼합물의 추출물과 편백 오일을 함유하는 여드름 또는 아토피 피부염의 예방 또는 치료용 조성물
CN117562844B (zh) 一种无酸祛痘组合物及其应用、日化品
CN100436442C (zh) 含类黄酮的组合物的产生方法及其应用
KR20150140833A (ko) 락토바실러스 펜토수스의 미용학적 및 약제학적 용도
WO2019088446A1 (fr) Composition d'atténuation des dégâts causés aux cellules cutanées humaines provoqués par les rayons ultraviolets, contenant un extrait d'hydrangea serrata
WO2013115456A1 (fr) Aliment, substance cosmétique, ou composition pharmaceutique contenant un extrait supercritique de gingembre et un extrait de résidu de persil japonais fermenté
KR101516866B1 (ko) 떡쑥 추출물을 유효성분으로 포함하는 여드름 치료 및 예방용 조성물
WO2018203668A1 (fr) Composition de préparation cutanée à usage externe destinée à soulager une peau atopique et produit cosmétique la contenant
KR20220073983A (ko) 유산균 쌀 발효물을 포함하는 피부 마이크로비옴 기능 증진용 조성물
KR102214985B1 (ko) 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물
KR102300581B1 (ko) 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물
WO2022191551A1 (fr) Composition comprenant du cannabigérol
WO2016010283A1 (fr) Composition contenant de l'huile de glycine gracilis
WO2022139458A1 (fr) Composition de soins de la peau
WO2020111757A1 (fr) Composition contenant de la quercétine, de la génistéine et de l'acide alpha-lipoïque, pour soulager la peau acnéique
KR20140013796A (ko) 진세노사이드 ｆ1을 유효 성분으로 포함하는 피부 염증질환 개선용 화장료 조성물
KR101273027B1 (ko) 캄페롤을 유효성분으로 함유하는 피지 분비 억제용 및항비만용 조성물
WO2016171482A1 (fr) Composition cosmétique comprenant un extrait d'apitoxine, et son procédé de fabrication
WO2020111540A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du vieillissement ou de maladies associées au vieillissement, comprenant un complexe d'anthocyanine-polysaccharide en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12867458

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12867458

Country of ref document: EP

Kind code of ref document: A1